Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients (Q34604408)

3 August 2017

1 reference

title

Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients (English)

1 reference

3 August 2017

0 references

1 reference

1 reference

1

Marta Boffito

1 reference

3 August 2017

Diego Miralles

2

1 reference

PubMed ID

19203907

3 August 2017

Andrew Hill

series ordinal

3

1 reference

3 August 2017

1 November 2008

1 reference

3 August 2017

1 reference

3 August 2017

9

1 reference

3 August 2017

6

1 reference

3 August 2017

418-427

1 reference

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.

3 August 2017

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT0906-418

21 January 2018

Identifiers

DOI

10.1310/HCT0906-418

1 reference

3 August 2017

1 reference

PubMed ID

19203907